Lineage Cell Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: March 5, 2026 | LINEAGE CELL THERAPEUTICS, INC. | |
|---|---|---|
| By: | /s/ Brian M. Culley | |
| Brian M. Culley | ||
| Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Brian M. Culley | Chief Executive Officer and Director | March 5, 2026 |
| BRIAN M. CULLEY | (Principal Executive Officer) | |
| /s/ Jill Ann Howe | Chief Financial Officer | March 5, 2026 |
| JILL ANN HOWE | (Principal Financial and Accounting Officer) | |
| /s/ Deborah Andrews | Director | March 5, 2026 |
| DEBORAH ANDREWS | ||
| /s/ Dipti Amin | Director | March 5, 2026 |
| DIPTI AMIN | ||
| /s/ Neal C. Bradsher | Director | March 5, 2026 |
| NEAL C. BRADSHER | ||
| /s/ Anula Jayasuriya | Director | March 5, 2026 |
| ANULA JAYASURIYA | ||
| /s/ Michael H. Mulroy | Director | March 5, 2026 |
| MICHAEL H. MULROY | ||
| /s/ Angus C. Russell | Director | March 5, 2026 |
| ANGUS C. RUSSELL | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.